Study published in Nature Cell Biology is fundamental in understanding the ways in which cancer cells can develop drug resistance, one of the main causes of relapse.
Cancer care in India is moving beyond AIIMS or Tata Memorial. Doctors are shifting to their hometowns to open hospitals, and district centres are starting to offer chemo and diagnostics.
Cancer care in India is marked by barriers of access & disparities in availability of quality care. Daycare centres at district hospitals could save patients up to Rs 10,000 cr annually.
Navjot Singh Sidhu says his wife, diagnosed with stage 4 breast cancer, followed a diet that included neem, turmeric, sour fruits. Oncologists say complementary therapies not treatment.
Definite steps are now being taken to understand the profile of cancer in the Indian population. Expect rapid progress in cancer care in India in the coming years.
Without widespread access to biosimilars, thousands of cancer patients are losing their battle. Life-saving treatment is not a privilege but a right. The government should understand this.
CAR T-cell therapy's a form of immunotherapy that uses body's immune cells called T-cells, a type of lymphocyte or white blood cell. It has been approved for various types of blood cancers.
Findings by Tata Memorial Centre suggest that resveratrol, when given with miniscule doses of copper, can reduce rate of metastasis & treatment-related toxicity in cancer patients.
Patients already registering for CAR T-cell therapy, developed indigenously by ImmunoACT under the name NexCAR19. It will be used to treat leukemia & refractory or relapsed lymphoma.
An average Lajpat Nagar playboy knows that women will reply to his Instagram story of the chicken curry he cooked for lunch. And he is proven right, every single time.
The concern is not that 2025’s rally was irrational, but that it may be difficult to repeat. Outlooks remain anchored to AI investment and growth without reigniting inflation.
If deal goes through, Greece will be 2nd foreign country to procure vehicle. Morocco was first; TATA Group has set up manufacturing unit there with minimum 30 percent indigenous content.
Many of you might think I got something so wrong in National Interest pieces written this year. I might disagree! But some deserve a Mea Culpa. I’d deal with the most recent this week.
COMMENTS